Diagnosis and classification of idiopathic inflammatory myopathies
Open Access
- 19 June 2016
- journal article
- review article
- Published by Wiley in Journal of Internal Medicine
- Vol. 280 (1), 39-51
- https://doi.org/10.1111/joim.12524
Abstract
The idiopathic inflammatory myopathies (IIMs) are a heterogeneous group of diseases, collectively termed myositis, sharing symptoms of muscle weakness, fatigue and inflammation. Other organs are frequently involved, supporting the notion that these are systemic inflammatory diseases. The IIMs can be subgrouped into dermatomyositis, polymyositis and inclusion body myositis. The myositis‐specific autoantibodies (MSAs) identify other and often more distinct clinical phenotypes, such as the antisynthetase syndrome with antisynthetase autoantibodies and frequent interstitial lung disease and anti‐SRP and anti‐HMGCR autoantibodies that identify necrotizing myopathy. The MSAs are important both to support myositis diagnosis and to identify subgroups with different patterns of extramuscular organ involvement such as interstitial lung disease. Another cornerstone in the diagnostic procedure is muscle biopsy to identify inflammation and to exclude noninflammatory myopathies. Treatment effect and prognosis vary by subgroup. To develop new and better therapies, validated classification criteria that identify distinct subgroups of myositis are critical. The lack of such criteria was the main rationale for the development of new classification criteria for IIMs, which are summarized in this review; the historical background regarding previous diagnostic and classification criteria is also reviewed. As the IIMs are rare diseases with a prevalence of 10 in 100 000 individuals, an international collaboration was essential, as was the interdisciplinary effort including experts in adult and paediatric rheumatology, neurology, dermatology and epidemiology. The new criteria have been developed based on data from more than 1500 patients from 47 centres worldwide and are based on clinically easily available variables.Keywords
Funding Information
- National Institutes of Health
- National Institute of Environmental Health Sciences
This publication has 31 references indexed in Scilit:
- Diagnostic performance and validation of autoantibody testing in myositis by a commercial line blot assayRheumatology, 2010
- Novel conformation of histidyl–transfer RNA synthetase in the lungArthritis & Rheumatism, 2007
- International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathiesArthritis & Rheumatism, 2005
- 119th ENMC international workshop: Trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10–12 October 2003, Naarden, The NetherlandsNeuromuscular Disorders, 2004
- Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathiesRheumatology, 2001
- MRI guided muscle biopsy confirmed polymyositis diagnosis in a patient with interstitial lung diseaseAnnals Of The Rheumatic Diseases, 2001
- Inclusion body myositis and myopathiesAnnals of Neurology, 1995
- Polymyositis, Dermatomyositis, and Inclusion-Body MyositisNew England Journal of Medicine, 1991
- A COMPUTER-ASSISTED ANALYSIS OF 153 PATIENTS WITH POLYMYOSITIS AND DERMATOMYOSITISMedicine, 1977
- POLYMYOSITIS: ITS PRESENTATION, MORBIDITY AND MORTALITYBrain, 1975